Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
32.31M | 78.12M | 19.71M | 25.54M | 90.73M | Gross Profit |
32.31M | -99.53M | 13.38M | 20.49M | -67.26M | EBIT |
-251.15M | -169.18M | -225.95M | -193.15M | -134.84M | EBITDA |
-233.11M | -163.12M | -219.61M | -188.09M | -130.88M | Net Income Common Stockholders |
-237.09M | -153.22M | -204.35M | -185.11M | -109.41M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
269.91M | 323.11M | 437.37M | 619.91M | 511.77M | Total Assets |
341.59M | 499.15M | 514.32M | 677.48M | 572.60M | Total Debt |
35.03M | 36.54M | 43.95M | 26.38M | 26.14M | Net Debt |
-96.51M | -87.12M | -97.58M | -177.14M | -113.55M | Total Liabilities |
207.31M | 150.06M | 153.64M | 123.84M | 179.02M | Stockholders Equity |
134.27M | 349.10M | 360.68M | 553.64M | 393.59M |
Cash Flow | Free Cash Flow | |||
-219.11M | -136.90M | -181.47M | -171.78M | -187.00M | Operating Cash Flow |
-210.28M | -132.18M | -177.35M | -163.80M | -179.84M | Investing Cash Flow |
162.15M | -3.73M | 114.07M | -54.47M | -140.52M | Financing Cash Flow |
56.03M | 118.04M | 1.28M | 282.11M | 224.12M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
48 Neutral | $6.86B | 1.11 | -50.22% | 2.47% | 16.71% | 1.53% | |
46 Neutral | $2.80B | ― | -19.20% | ― | -89.95% | -123.71% | |
46 Neutral | $1.64B | ― | -43.94% | ― | -83.18% | -144.95% | |
42 Neutral | $139.84M | ― | -187.83% | ― | -67.20% | 64.66% | |
41 Neutral | $713.24M | ― | -54.00% | ― | 59.55% | 3.09% | |
39 Underperform | $92.93M | ― | -98.10% | ― | -58.64% | -40.05% | |
36 Underperform | $47.87M | ― | -295.35% | ― | 184.12% | 31.92% |
On March 18, 2025, Editas Medicine announced the resignation of Erick Lucera, its Executive Vice President and Chief Financial Officer, effective March 28, 2025. Amy Parison, who has been with the company since January 2025, will succeed him, bringing extensive experience from her previous roles at Rubius Therapeutics and Vertex Pharmaceuticals. The transition includes new compensation terms for Ms. Parison, highlighting her strategic importance to the company.
Editas Medicine announced new in vivo preclinical proof of concept data and outlined its strategic priorities and key milestones for 2025, aiming to advance its gene editing technologies targeting hematopoietic stem cells and liver cells. The company plans to declare two in vivo development candidates and expand its therapeutic possibilities, positioning itself as a leader in the in vivo gene editing field with a strong financial runway into 2027.